Skip to main content
Clinical Trials/JPRN-UMIN000001124
JPRN-UMIN000001124
Completed
未知

Clinical Assessment to Establish the Symptomatic Advantage of Rabeprazole: double-blind, randomized, placebo-controlled study in functional dyspepsia - CAESAR study

Office of CAESAR study0 sites120 target enrollmentApril 29, 2008

Overview

Phase
未知
Intervention
Not specified
Conditions
Functional Dyspepsia
Sponsor
Office of CAESAR study
Enrollment
120
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 29, 2008
End Date
January 1, 2009
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Office of CAESAR study

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Organic disease such as reflux esophagitis (\> grade A) and erosive gastritis. 2\. Patients with past history of gastrectomy 3\. NSAIDs or low\-dose aspirin \-related dyspepsia 4\. Patients with organic disease in the brain or with psychological disorders 5\. Patients with alcoholics or with drug dependence 6\. Severe endocrine disease including hyperthyroidism 7\. Severe diseases in heart, liver and kidney. Severe infectious or hemotological diseases 8\. Drug allegy for rabeprazole 9\. expectant mother, mother with breast\-feeding 10\. other not applicable person recognized by a doctor

Outcomes

Primary Outcomes

Not specified

Similar Trials